Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting.
The antifungal and antileishmanial agent amphotericin B (AmB) has been complexed with lipids to develop a less toxic formulation of AmB. Because lipid particles are phagocytized by the reticuloendothelial system, lipid associated AmB should be concentrated in infected macrophages of liver and spleen and be very effective against visceral leishmaniasis (VL) and systemic fungal infections. Therefore, AmB was formulated in trilaurin based nanosize lipid particles (emulsomes) stabilized by soya phosphatidylcholine (PC) as a new intravenous drug delivery system for macrophage targeting. Emulsomes were prepared by cast film technique followed by sonication to obtain particles of nanometric size range. Formulations were optimized for AmB to lipid ratio, sonication time and PC to trilaurin ratio. Emulsomes were modified by coating them with macrophage-specific ligand (O-palmitoyl mannan, OPM). The surface modified emulsomes and their plain counterparts were characterised for size, shape, lamellarity and entrapment efficiency. Fluorescence microscopy study showed significant localization of plain and coated emulsomes inside the liver and spleen cells of golden hamsters. In vivo organ distribution studies in albino rats demonstrated that extent of accumulation of emulsome entrapped AmB in macrophage rich organs, particularly liver, spleen and lungs was significantly high when compared against the free drug (AmB-deoxycholate or AmB-Doc). The rate and extent of accumulation were found to increase further on ligand anchoring. Further, a significantly higher (P < 0.05) drug concentration in the liver was estimated over a period of 24 h for OPM coated emulsomes than for plain emulsomes. We concluded that OPM coated emulsomes could fuse with the macrophages of liver and spleen due to ligand-receptor interaction and could target the bioactives inside them. The proposed plain and OPM coated emulsome based systems showed excellent potential for passive and active intramacrophage targeting, respectively and the approach could be a successful alternative to the currently available drug regimens of VL and systemic fungal infections.
Gupta
Swati
S
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour Vishwavidyalaya, Sagar, MP, India. swatig25@gmail.com
Vyas
Suresh P
SP
D000666:Amphotericin B / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D002784:Cholesterol / Q000737:chemistry; D006224:Cricetinae; D015195:Drug Design; D004355:Drug Stability; D008081:Liposomes; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008647:Mesocricetus; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry; D009928:Organ Specificity; D010316:Particle Size; D051381:Rats; D013499:Surface Properties; D014018:Tissue Distribution; D014280:Triglycerides / Q000737:chemistry
D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D008081:Liposomes; D014280:Triglycerides; C004565:trilaurin; D000666:Amphotericin B; D002784:Cholesterol